Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of nab-paclitaxel + S-1 as neoadjuvant therapy for borderline resectable pancreatic cancer
ChiCTR1800016899Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and tegafur in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Chinese PLA General Hospital. Primary endpoints: R0 resection rate and Disease-free survival. Started Jul 2018; status: recruiting.
02
Drugs
paclitaxeltegafur
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1800016899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016899.